Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosa Falcone

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 6, 2021
In silico drug repurposing in COVID-19: A network-based analysisPasquale Sibilio, Simone Bini, Giulia Fiscon, et al.
Cancers|October 16, 2025
Application of Radiomics in Melanoma: A Systematic Review and Meta-AnalysisRosa Falcone, Sofia Verkhovskaia, Francesca Romana Di Pietro, et al.
Cancers|July 18, 2020
Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the ThyroidValeria Pecce, Antonella Verrienti, Luana Abballe, et al.
Medical Oncology (Northwood, London, England)|February 2, 2015
Continuous, low-dose capecitabine for patients with recurrent colorectal cancerAdriana Romiti, Concetta Elisa Onesti, Michela Roberto, et al.
Cancers|October 23, 2021
Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical TrialsSimona Duranti, Alessandra Fabi, Marco Filetti, et al.
Anti-Cancer Drugs|August 25, 2016
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancerAdriana Romiti, Michela Roberto, Chiara D'Antonio, et al.
Frontiers in Pharmacology|January 22, 2026
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case seriesRosa Falcone, Alessandra Frezzolini, Emanuele Bruni, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 2, 2018
IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?Livia Lamartina, Teresa Montesano, Rosa Falcone, et al.
Anti-Cancer Drugs|November 16, 2016
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOXConcetta E Onesti, Andrea Botticelli, Marco La Torre, et al.
Medical Oncology (Northwood, London, England)|June 21, 2018
Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survivalMichela Roberto, Andrea Botticelli, Lidia Strigari, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 6, 2021
In silico drug repurposing in COVID-19: A network-based analysisPasquale Sibilio, Simone Bini, Giulia Fiscon, et al.
Cancers|October 16, 2025
Application of Radiomics in Melanoma: A Systematic Review and Meta-AnalysisRosa Falcone, Sofia Verkhovskaia, Francesca Romana Di Pietro, et al.
Cancers|July 18, 2020
Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the ThyroidValeria Pecce, Antonella Verrienti, Luana Abballe, et al.
Medical Oncology (Northwood, London, England)|February 2, 2015
Continuous, low-dose capecitabine for patients with recurrent colorectal cancerAdriana Romiti, Concetta Elisa Onesti, Michela Roberto, et al.
Cancers|October 23, 2021
Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical TrialsSimona Duranti, Alessandra Fabi, Marco Filetti, et al.
Anti-Cancer Drugs|August 25, 2016
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancerAdriana Romiti, Michela Roberto, Chiara D'Antonio, et al.
Frontiers in Pharmacology|January 22, 2026
Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case seriesRosa Falcone, Alessandra Frezzolini, Emanuele Bruni, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 2, 2018
IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?Livia Lamartina, Teresa Montesano, Rosa Falcone, et al.
Anti-Cancer Drugs|November 16, 2016
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOXConcetta E Onesti, Andrea Botticelli, Marco La Torre, et al.
Medical Oncology (Northwood, London, England)|June 21, 2018
Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survivalMichela Roberto, Andrea Botticelli, Lidia Strigari, et al.
Pageof 7